润肤浴添加剂治疗儿童湿疹(BATHE):多中心实用性平行组随机对照试验的临床与成本效果
该多中心实用性随机对照试验纳入483名1至11岁符合英国特应性皮炎诊断标准的儿童,比较常规治疗中加用润肤浴添加剂与不加用对湿疹控制的效果。主要结局为16周内每周POEM评分,结果显示两组间无统计学显著差异,校正后差值0.41分(95%CI -0.27至1.10),低于POEM最小临床重要差异3分,次要结局、经济结局和不良反应均无差异。结论认为无证据支持在儿童湿疹标准管理中常规加入润肤浴添加剂。
要点
- 在儿童湿疹标准管理中加用润肤浴添加剂,16周POEM评分与不加用组无显著差异。
- 校正后POEM差值0.41分(95%CI -0.27至1.10),低于最小临床重要差异3分。
- 两组在次要结局、经济结局及不良反应方面均无差异。
核心结论
- 本试验未发现润肤浴添加剂在儿童湿疹标准管理中具有临床获益的证据。
- 需进一步研究润肤剂和肥皂替代品的最佳使用方案。
研究设计与样本
- 实用性随机开放标签优效性试验,两组平行设计。
- 在威尔士及英格兰西部和南部的96家全科诊所开展。
- 纳入483名1至11岁符合英国特应性皮炎诊断标准的儿童,排除湿疹极轻及每周洗澡少于1次的儿童。
- 干预组由常规临床团队处方润肤浴添加剂并规律使用12个月,对照组不使用浴添加剂12个月,两组均继续标准湿疹管理包括润肤剂。
- 主要结局为16周内每周患者导向湿疹测量(POEM,0-7轻度,8-16中度,17-28重度)评分。
主要发现
- 483名儿童随机分组,1名退出,482名进入试验;51%为女孩(244/482),84%为白人(447/470),平均年龄5岁。
- 96%(461/482)完成至少一次基线后POEM并纳入分析,77%(370/482)完成超过80%时间点的主要结局问卷。
- 浴添加剂组基线平均POEM评分9.5(SD 5.7),无浴添加剂组10.1(SD 5.8)。
- 16周期间浴添加剂组平均POEM评分7.5(SD 6.0),无浴添加剂组8.4(SD 6.0)。
- 校正基线严重度及混杂因素(种族、外用糖皮质激素使用、肥皂替代品使用)并考虑中心内聚集和个体内重复测量后,无浴添加剂组POEM评分比浴添加剂组高0.41分(95%CI -0.27至1.10)。
关键数值与推荐
- POEM评分0-7为轻度,8-16为中度,17-28为重度。
- POEM最小临床重要差异为3分。
- 校正后组间POEM差值0.41分(95%CI -0.27至1.10),低于最小临床重要差异3分。
临床怎么用
- 全科医生在儿童湿疹标准管理中不应常规处方润肤浴添加剂,因缺乏临床获益证据。
- 应继续关注润肤剂和肥皂替代品的优化使用方案。
局限性
- 开放标签设计可能引入偏倚。
- 77%的参与者完成超过80%时间点的主要结局问卷,存在失访。
- 排除湿疹极轻及每周洗澡少于1次的儿童,结果外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the clinical effectiveness and cost effectiveness of including emollient bath additives in the management of eczema in children. DESIGN: Pragmatic randomised open label superiority trial with two parallel groups. SETTING: 96 general practices in Wales and western and southern England. PARTICIPANTS: 483 children aged 1 to 11 years, fulfilling UK diagnostic criteria for atopic dermatitis. Children with very mild eczema and children who bathed less than once weekly were excluded. INTERVENTIONS: Participants in the intervention group were prescribed emollient bath additives by their usual clinical team to be used regularly for 12 months. The control group were asked to use no bath additives for 12 months. Both groups continued with standard eczema management, including leave-on emollients, and caregivers were given standardised advice on how to wash participants. MAIN OUTCOME MEASURES: The primary outcome was eczema control measured by the patient oriented eczema measure (POEM, scores 0-7 mild, 8-16 moderate, 17-28 severe) weekly for 16 weeks. Secondary outcomes were eczema severity over one year (monthly POEM score from baseline to 52 weeks), number of eczema exacerbations resulting in primary healthcare consultation, disease specific quality of life (dermatitis family impact), generic quality of life (child health utility-9D), utilisation of resources, and type and quantity of topical corticosteroid or topical calcineurin inhibitors prescribed. RESULTS: 483 children were randomised and one child was withdrawn, leaving 482 children in the trial: 51% were girls (244/482), 84% were of white ethnicity (447/470), and the mean age was 5 years. 96% (461/482) of participants completed at least one post-baseline POEM, so were included in the analysis, and 77% (370/482) completed questionnaires for more than 80% of the time points for the primary outcome (12/16 weekly questionnaires to 16 weeks). The mean baseline POEM score was 9.5 (SD 5.7) in the bath additives group and 10.1 (SD 5.8) in the no bath additives group. The mean POEM score over the 16 week period was 7.5 (SD. 6.0) in the bath additives group and 8.4 (SD 6.0) in the no bath additives group. No statistically significant difference was found in weekly POEM scores between groups over 16 weeks. After controlling for baseline severity and confounders (ethnicity, topical corticosteroid use, soap substitute use) and allowing for clustering of participants within centres and responses within participants over time, POEM scores in the no bath additives group were 0.41 points higher than in the bath additives group (95% confidence interval -0.27 to 1.10), below the published minimal clinically important difference for POEM of 3 points. The groups did not differ in secondary outcomes, economic outcomes, or adverse effects. CONCLUSIONS: This trial found no evidence of clinical benefit from including emollient bath additives in the standard management of eczema in children. Further research is needed into optimal regimens for leave-on emollient and soap substitutes. TRIAL REGISTRATION: Current Controlled Trials ISRCTN84102309.
引用
- Santer M, Ridd MJ, Francis NA, et al. Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness. BMJ. 2018. PMID: 29724749. doi:10.1136/bmj.k1332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。